Rituximab in Hodgkin lymphoma: Is the target always a hit?

Cancer Treatment Reviews

Volumn 37, Issue 5, 2011, Pages 385-390

  Saini, Kamal S ^a   Azim, Hatem A ^a   Cocorocchio, Emilia ^b   Vanazzi, Anna ^b   Saini, Monika Lamba ^c   Raviele, Paola Rafaniello ^b   Pruneri, Giancarlo ^b   Peccatori, Fedro A ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Anti CD20 monoclonal antibodies; Classic Hodgkin lymphoma; Lymphocyte predominant Hodgkin lymphoma; Rituximab; Targeted therapy

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; NAVELBINE; OCRELIZUMAB; OFATUMUMAB; PREDNISONE; PROCARBAZINE; RITUXIMAB; VELTUZUMAB; VINBLASTINE; VINCRISTINE;

CLASSICAL HODGKIN LYMPHOMA; HODGKIN DISEASE; HUMAN; ISOTOPE LABELING; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; REVIEW; SYSTEMATIC REVIEW; XENOGRAFT;

EID: 79957472810     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.11.005     Document Type: Review

References (50)

1. Jost L.M., Stahel R.A. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol 2005, 16(Suppl. 1):i54-i55.
2. Nogova L., Reineke T., Brillant C., Sieniawski M., Rudiger T., Josting A., et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008, 26(3):434-439.
3. Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A. Lymphocyte-predominant Hodgkin lymphoma - clinical features and treatment outcomes from a 30-year experience. Ann Oncol. March 23, 2010 [Epub ahead of print].
4. Maeda L.S., Advani R.H. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 2009, 21(5):397-400.
5. Ram R., Ben-Bassat I., Shpilberg O., Polliack A., Raanani P. The late adverse events of rituximab therapy - rare but there!. Leuk. Lymphoma 2009, 50(7):1083-1095.
6. Ekstrand B.C., Lucas J.B., Horwitz S.M., Fan Z., Breslin S., Hoppe R.T., et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003, 101(11):4285-4289.
7. Schulz H., Rehwald U., Morschhauser F., Elter T., Driessen C., Rudiger T., et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008, 111(1):109-111.
8. Younes A., Romaguera J., Hagemeister F., McLaughlin P., Rodriguez M.A., Fiumara P., et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003, 98(2):310-314.
9. Anagnostopoulos I., Hansmann M.L., Franssila K., Harris M., Harris N.L., Jaffe E.S., et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000, 96(5):1889-1899.
10. von Wasielewski R., Werner M., Fischer R., Hansmann M.L., Hubner K., Hasenclever D., et al. Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group. Am J Pathol 1997, 150(3):793-803.
11. Boudova L., Torlakovic E., Delabie J., Reimer P., Pfistner B., Wiedenmann S., et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003, 102(10):3753-3758.
12. Hedvat C.V., Hegde A., Chaganti R.S., Chen B., Qin J., Filippa D.A., et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002, 33(10):968-974.
13. Rassidakis G.Z., Medeiros L.J., Viviani S., Bonfante V., Nadali G.P., Vassilakopoulos T.P., et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002, 20(5):1278-1287.
14. Fromm J.R., Thomas A., Wood B.L. Flow cytometry can diagnose classical Hodgkin lymphoma in lymph nodes with high sensitivity and specificity. Am J Clin Pathol 2009, 131(3):322-332.
15. Rudiger T., Ott G., Ott M.M., Muller-Deubert S.M., Muller-Hermelink H.K. Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Am J Surg Pathol 1998, 22(10):1184-1191.
16. Marafioti T., Hummel M., Foss H.D., Laumen H., Korbjuhn P., Anagnostopoulos I., et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000, 95(4):1443-1450.
17. Kanzler H., Kuppers R., Hansmann M.L., Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996, 184(4):1495-1505.
18. Zukerberg L.R., Collins A.B., Ferry J.A., Harris N.L. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol 1991, 139(3):475-483.
19. Boye J., Elter T., Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003, 14(4):520-535.
20. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980, 125(4):1678-1685.
21. Press O.W., Appelbaum F., Ledbetter J.A., Martin P.J., Zarling J., Kidd P., et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987, 69(2):584-591.
22. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256(5517):495-497.
23. Maloney D.G., Smith B., Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002, 29(1 Suppl. 2):2-9.
24. Oflazoglu E., Audoly L.P. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010, 2(1):14-19.
25. Decaudin D., Marszak F.B., Couturier J., Mathiot C., Martin A., Nemati F., et al. High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice. Anticancer Drugs 2006, 17(6):685-695.
26. Meggetto F., Muller C., Henry S., Selves J., Mariame B., Brousset P., et al. Epstein-Barr virus (EBV)-associated lymphoproliferations in severe combined immunodeficient mice transplanted with Hodgkin's disease lymph nodes: implications of EBV-positive bystander B lymphocytes rather than EBV-infected Reed-Sternberg cells. Blood 1996, 87(6):2435-2442.
27. Rehwald U., Schulz H., Reiser M., Sieber M., Staak J.O., Morschhauser F., et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003, 101(2):420-424.
28. Horning S.J., Bartlett N.L., Breslin S., Advani R.H., Hoppe R.T., Ekstrand B.C., et al. Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin's Disease (NLPHD). Blood 2007, 110(11):644.
29. Unal A., Sari I., Deniz K., Ozkan M., Kontas O., Eser B., et al. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leuk Lymphoma 2005, 46(11):1613-1617.
30. Boulanger E., Meignin V., Leverger G., Solal-Celigny P. Rituximab monotherapy in nodular lymphocyte-predominant Hodgkin's disease. Ann Oncol 2003, 14(1):171.
31. Keilholz U., Szelenyi H., Siehl J., Foss H.D., Knauf W., Thiel E. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono-clonal antibody) and interleukin-2. Leuk Lymphoma 1999, 35(5-6):641-642.
32. Weine D.M., Gelfand R.M., Fraser C.R., Weg A.L. The first reported case of nodular lymphocyte-predominant Hodgkin's lymphoma of the appendix. Am J Gastroenterol 2009, 104(7):1860-1861.
33. Lush R.J., Jones S.G., Haynes A.P. Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin's disease: long-term follow-up of allografting and monoclonal antibody therapy. Br J Haematol 2001, 114(3):734-735.
34. Pijuan L., Vicioso L., Bellosillo B., Ferrer M.D., Baro T., Pedro C., et al. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection. Am J Surg Pathol 2005, 29(10):1399-1403.
35. Culic S., Armanda V., Kuljis D., Kuzmic I., Pranic-Kragic A., Jankovic S. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl. Pediatr Hematol Oncol 2006, 23(8):661-666.
36. Galan L., Sanchez A.C., Cantos B., Provencio M. Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma. Clin Transl Oncol 2010, 12(5):384-386.
37. Azim H.A., Pruneri G., Cocorocchio E., Cinieri S., Raviele P.R., Bassi S., et al. Rituximab in lymphocyte-predominant Hodgkin disease. Oncology 2009, 76(1):26-29.
38. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20(10):2453-2463.
39. Wiseman G.A., Kornmehl E., Leigh B., Erwin W.D., Podoloff D.A., Spies S., et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003, 44(3):465-474.
40. Morschhauser F., Illidge T., Huglo D., Martinelli G., Paganelli G., Zinzani P.L., et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007, 110(1):54-58.
41. Morschhauser F., Radford J., Van Hoof A., Vitolo U., Soubeyran P., Tilly H., et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26(32):5156-5164.
42. Zojer N., Mirzaei S., Ludwig H. Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan. Eur J Haematol 2008, 81(4):322-324.
43. Schnell R., Dietlein M., Schomacker K., Kobe C., Borchmann P., Schicha H., et al. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Onkologie 2008, 31(1-2):49-51.
44. Younes A., Wong F. Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma. Ann Oncol 2009, 20(6):1147-1148.
45. Yaich S., Zagdane S., Charfeddine K., Hssairi D., Hachicha J. Simultaneous Hodgkin's disease and Kaposi sarcoma in a renal transplant recipient. Saudi J Kidney Dis Transpl 2010, 21(2):306-309.
46. Al-Ali H.K., Wittekind C., Niederwieser D. Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab. Dtsch Med Wochenschr 2007, 132(33):1688-1691.
47. Stern M., Herrmann R., Rochlitz C., Dirnhofer S., Pless M. A case of post-transplant lymphoproliferative disease presenting as CD20-expressing, Epstein-Barr-virus positive Hodgkin lymphoma. Eur J Haematol 2005, 74(3):267-270.
48. Falchi L., Capello D., Palumbo B., Rauco A., Emili R., Cianciulli M., et al. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy. Eur J Haematol 2007, 79(5):455-461.
49. Diehl V., Harris N.L., Mauch P.M. Hodgkin lymphoma. Cancer: Principles and Practice of Oncology 2008, 2207-2208. Lippincott Williams and Wilkins, Philadelphia. 8th ed. V.T. DeVita, T.S. Lawrence, S.A. Rosenberg (Eds.).
50. Ibom V.K., Prosnitz R.G., Gong J.Z., Moore J.O., DeCastro C.M., Prosnitz L.R., et al. Rituximab in lymphocyte predominance Hodgkin's disease: a case series. Clin Lymphoma 2003, 4(2):115-118.